PGP and cancer: From a pharmacological perspective, when designing novel small molecule hydrophobic anticancer drugs, one should avoid the introduction of positively charged residues and/or other moieties that may enhance plasma membrane residence time, hence leaving for P‐gp ample time to recognize and efficiently extrude such novel chemotherapeutics, resulting in cancer MDR.